Investigational drug product for treatment of heavy metal poisoning
Pharmaceutical compound
3,4,3-LI(1,2-HOPO) Legal status
N ,N′ -1,4-Butanediylbis[N -[3-[[(1,6-dihydro-1-hydroxy-6-oxo-2-pyridinyl)carbonyl]amino]propyl]-1,6-dihydro-1-hydroxy-6-oxo-2-pyridinecarboxamide]
CAS Number PubChem CID ChemSpider UNII ChEMBL CompTox Dashboard (EPA ) Formula C 34 H 38 N 8 O 12 Molar mass −1 3D model (JSmol )
O=C1C=CC=C(C(=O)NCCCN(C(=O)C2=CC=CC(=O)N2O)CCCCN(C(=O)C3=CC=CC(=O)N3O)CCCNC(=O)C4=CC=CC(=O)N4O)N1O
InChI=1S/C34H38N8O12/c43-27-13-3-9-23(39(27)51)31(47)35-17-7-21-37(33(49)25-11-5-15-29(45)41(25)53)19-1-2-20-38(34(50)26-12-6-16-30(46)42(26)54)22-8-18-36-32(48)24-10-4-14-28(44)40(24)52/h3-6,9-16,51-54H,1-2,7-8,17-22H2,(H,35,47)(H,36,48)
Key:KUWKQASGHNTJAT-UHFFFAOYSA-N
HOPO 14-1 is an investigational drug product for removing radioactive contaminants from the body. It is an oral capsule designed to act as a defence against radioactive threats such as nuclear power plant accidents or dirty bomb attacks.[ 1] [ 2] hydroxypyridinone ligand 3,4,3-LI(1,2-HOPO), which is a powerful chelating agent.[ 1] [ 3] [ 4] heavy metal toxicity , including lead poisoning and exposure to gadolinium from MRI contrast agents .[ 5] [ 6] [ 7] [ 8] Lawrence Berkeley National Laboratory by actinide chemist Rebecca Abergel . Abergel and former postdoc Julian Avery Rees co-founded HOPO Therapeutics , a company commercializing HOPO 14-1 and other treatments for heavy metal poisoning.
References
^ a b "First-in-human trial of oral drug to remove radioactive contamination begins" . National Institutes of Health (NIH) . 2023-05-15. Retrieved 2023-05-16 .^ Roberts M (2023-05-16). "Dirty-bomb antidote: Drug trial begins in US" . BBC News . Retrieved 2023-05-16 . ^ Wang Q, Liu Z, Song YF, Chai Z, Wang D (March 2023). "Chelation Behaviors of 3,4,3-LI(1,2-HOPO) with Lanthanides and Actinides Implicated by Molecular Dynamics Simulations". Inorganic Chemistry . 62 (10): 4304– 4313. doi :10.1021/acs.inorgchem.2c04460 . PMID 36847745 . S2CID 257218983 . ^ Abergel RJ, Durbin PW, Kullgren B, Ebbe SN, Xu J, Chang PY, et al. (September 2010). "Biomimetic actinide chelators: an update on the preclinical development of the orally active hydroxypyridonate decorporation agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO)" . Health Physics . 99 (3): 401– 407. doi :10.1097/HP.0b013e3181c21273 . PMC 2921233 PMID 20699704 . ^ Rees JA, Deblonde GJ, An DD, Ansoborlo C, Gauny SS, Abergel RJ (March 2018). "Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents" . Scientific Reports . 8 (1): 4419. Bibcode :2018NatSR...8.4419R . doi :10.1038/s41598-018-22511-6 . PMC 5849765 PMID 29535330 . ^ "This Anti-Nuclear-Contimation Pill Could Also Help MRI Patients" . Lawrence Berkeley National Laboratory (Berkeley Lab) . 2019-09-12. Retrieved 2023-05-29 .^ "Rebecca Abergel - Bakar Fellows Program" . Bakar Fellows Program, UC Berkeley . 2021-10-21. Retrieved 2023-05-29 .^ "HOPO Therapeutics" . HOPO Therapeutics, Inc . 2023-05-29. Retrieved 2023-05-29 .
See also
.svg)
